Market open
Cabaletta Bio/$CABA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cabaletta Bio
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Ticker
$CABA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
137
Website
Cabaletta Bio Metrics
BasicAdvanced
$224M
Market cap
-
P/E ratio
-$1.92
EPS
2.40
Beta
-
Dividend rate
Price and volume
Market cap
$224M
Beta
2.4
52-week high
$26.35
52-week low
$3.47
Average daily volume
853K
Financial strength
Current ratio
11.523
Quick ratio
11.354
Total debt to equity
3.709
Management effectiveness
Return on assets (TTM)
-31.13%
Return on equity (TTM)
-48.16%
Valuation
Price to book
1.11
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
-2.843
Growth
Earnings per share change (TTM)
12.11%
3-year earnings per share growth (CAGR)
5.84%
What the Analysts think about Cabaletta Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cabaletta Bio stock.
Cabaletta Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cabaletta Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cabaletta Bio News
AllArticlesVideos
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
Seeking Alpha·2 weeks ago
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
GlobeNewsWire·1 month ago
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cabaletta Bio stock?
Cabaletta Bio (CABA) has a market cap of $224M as of November 08, 2024.
What is the P/E ratio for Cabaletta Bio stock?
The price to earnings (P/E) ratio for Cabaletta Bio (CABA) stock is 0 as of November 08, 2024.
Does Cabaletta Bio stock pay dividends?
No, Cabaletta Bio (CABA) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Cabaletta Bio dividend payment date?
Cabaletta Bio (CABA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cabaletta Bio?
Cabaletta Bio (CABA) has a beta rating of 2.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.